Michael J. Fisch - Böcker

Patients with advanced cancer increasingly receive end-of-life care from a variety of health care professionals, physicians and nurses. These professionals need to be able to assess the original diagnosis and the appropriateness of patient referral, set a treatment or palliation program, and recognise and plan for the clinical problems associated with specific primary tumors. This is the first comprehensive source of information available at a level between specialist oncology texts and nursing texts. Two eminent physicians from one of the world's foremost cancer centers have drawn together a remarkable team to provide a handbook which covers the full range of problems the healthcare workforce caring for these patients will encounter. This highly accessible text covers general principles in oncology, the primary tumors one by one, and management of specific symptoms and syndromes. It will be invaluable to primary care physicians, surgeons, nurses, therapists and trainees.

Cancer Symptom Science is the first interdisciplinary compilation of research on the mechanisms underlying the expression of cancer-related symptoms. It presents innovations in clinical, animal and in vitro research, research methods in brain imaging, and statistical-descriptive approaches to understanding the mechanistic basis of symptom expression. This volume also provides perspectives from patients, government and industry. By collecting and synthesizing the developing threads of new approaches to understanding cancer-related symptoms, the book promotes a pioneering framework for merging behavioral and biological disciplines to clarify mechanisms of symptom evolution, incorporating new technologies, testing novel agents for symptom control, and improving patient functioning and quality of life both during and after cancer treatment. With an expert editorial team led by Charles S. Cleeland, an internationally-recognized leader in cancer pain assessment and treatment, this is essential reading for surgical, clinical and medical oncologists, academic researchers, and pharmaceutical companies developing new agents to control symptom expression.